

LAURUS LABS DONATES HYDROXYCHLOROQUINE (HCQ) IP 200MG TABLETS & INR 50 LAKHS FUND TO FIGHT THE COVID-19 PANDEMIC IN TELANGANA AND ANDHRA PRADESH STATES.

Hyderabad, March 26, 2020, Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010)

COVID-19 is ravaging the world. Governments and public institutions are pulling out all stops to suppress the spread of this pandemic. At the moment, the expert consensus is that we need a good balance of suppression and mitigation initiatives to beat this virulent disease. It is a long and hard battle ahead for all, for the people and for the Governments across the globe.

On the mitigation side, The National Task Force for COVID 19, constituted by ICMR recommended the use Hydroxychloroquine for prophylaxis of SARS –Cov2 infection for high risk population under the medical supervision.

As a responsible corporate citizen, Laurus Labs Limited extended its support to Governments of Telangana and Andhra Pradesh in the fight to save the lives of those affected and may affect due to spread in both the states.

Dr. Satyanarayana Chava, Founder & CEO, Laurus labs, accompanied by Mr. Chandrakanth Chereddi, Executive Director, Mr. Krishna Chaitanya Chava, Executive Vice President, Corporate Development, Synthesis and Ingredients, Laurus Labs met Sri. Chandrasekhar Rao, Honorable Chief Minister of Telangana at his office and donated 1 lakh tablets of Hydroxychloroquine (HCQ) Tablets IP 200mg, as mitigation initiative and also donated a cheque of INR 50 Lakhs for other supporting suppression measures in the state of Telangana.

In a similar way at Visakhapatnam, Andhra Pradesh, Mr. Narasimha Rao Chava, Vice President, Human Resources, Laurus Labs met V. Vinay Chand IAS, District Collector and Magistrate, and donated 1 lakh tablets of Hydroxychloroquine (HCQ) Tablets IP 200mg, as mitigation initiative and also donated a cheque of INR 50 Lakhs for other supporting suppression of the spread measures in the state of Andhra Pradesh.

About Laurus Labs Limited

Laurus Labs is a leading research driven Pharmaceutical Manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma, and Gastroenterology. We are thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe and Low Middle-Income Countries (LMIC). We are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business. Most of our manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UK-MHRA, etc. Our approach remains to identify and invest ahead of time with strategic investments in State-of-the-Art R&D and Manufacturing Infrastructure enabling us to become a quality supplier of high volume products. Corporate Identification No: L24239AP2005PLC047518

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

Pavan Kumar N

Laurus Labs Ltd.

Tel: +91 40 3980 4380, 7337353848

Email: mediarelations@lauruslabs.com

A handwritten signature in purple ink, appearing to read "P. K. N." with a long horizontal stroke extending to the right.

DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.